Skip to Content

Trelegy Ellipta Approval History

  • FDA approved: Yes (First approved September 18th, 2017)
  • Brand name: Trelegy Ellipta
  • Generic name: fluticasone furoate, umeclidinium and vilanterol
  • Company: GlaxoSmithKline
  • Treatment for: COPD

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is an inhaled corticosteroid, long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) combination for the treatment of patients with chronic obstructive pulmonary disease (COPD).

Development History and FDA Approval Process for Trelegy Ellipta

DateArticle
Sep 18, 2017Approval FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD
Nov 21, 2016GSK Files Regulatory Submission in US for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD
Feb  9, 2015GSK and Theravance Announce Start of Phase III Lung Function Study with ‘Closed’ Triple Combination Treatment FF/UMEC/VI for COPD

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide